Nektar Therapeutics (NKTR) presented data at the American Association for Cancer Research 100th Annual Meeting demonstrating that NKTR-105, a novel PEGylated form of docetaxel, has superior antitumor activity, as well as greater and sustained exposure in plasma and tumor tissue, over docetaxel in preclinical models.
In a comparative study of NKTR-105 and docetaxel, NKTR-105 treatment significantly delayed tumor growth as compared to docetaxel , which was associated with greater and sustained tumor exposure to docetaxel after NKTR-105 administration.
In previous preclinical studies, NKTR-105 demonstrated superior antitumor activity with no neutropenia in multiple tumor models, indicating that NKTR-105 may enable sustained therapeutic levels of docetaxel without the myelosuppression that is a dose-limiting toxicity for this widely-used cancer therapy.
NKTR-105 is currently being evaluated in a Phase 1 clinical trial in cancer patients. In the current trial of NKTR-105, the compound has required no pre-treatment with corticosteroids and shown no evidence of neutropenia in patients to date.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.